Related Experiment Video
Updated: Jul 20, 2025
03:25
Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
Published on: June 16, 2022
932
First safety outcomes for rigicon conticlassic® artificial urinary sphincter
Steven K Wilson1, Eric Chung2, Brian Langford3
1Institute for Urologic Excellence, La Quinta, CA, USA.
International Journal of Impotence Research
|August 5, 2023
Summary
The Rigicon ContiClassic® sphincter device shows promising early safety and effectiveness for treating male stress urinary incontinence, with outcomes comparable to existing treatments.
Area of Science:
- Urology
- Medical Devices
- Surgical Innovation
Background:
- Male stress urinary incontinence (SUI) significantly impacts quality of life.
- Surgical management options for SUI are continually evolving.
- The Rigicon ContiClassic® is a novel sphincteric device introduced for SUI treatment.
Purpose of the Study:
- To evaluate the initial surgical outcomes and safety profile of the Rigicon ContiClassic® device.
- To assess the early performance of this new device in a cohort of patients.
Main Methods:
- Prospective evaluation of the first 116 patients implanted with the Rigicon ContiClassic® device.
- Data collection via patient information forms and surgical team reports.
- Analysis of patient demographics, surgical details, and incontinence etiology.
Main Results:
- The mean patient age was 68.3 years, with post-radical prostatectomy SUI being the most common indication (58.6%).
- The device demonstrated a revision rate of 6.90% (fluid loss, sizing issues, dissatisfaction).
- No infections were reported; 12-month survival rate was 93.2% via Kaplan-Meier analysis.
Conclusions:
- The Rigicon ContiClassic® device exhibits favorable early safety outcomes.
- Its performance appears comparable to other available sphincteric devices for male SUI.
- Further long-term studies are warranted to confirm sustained efficacy and safety.
